It is not approved for therapeutic or human use
Eli Lilly, the maker of Mounjaro and Zepbound, is urging the court to impose stricter diagnostic proof requirements in the ongoing GLP-1 gastroparesis litigation
The failure of these treatments to restore function and slow functional disease progression can be traced to their inability to correct the underlying cause of the dysfunction- diminished synaptic connectivity among neurons in the striatum and neuronal loss in the substantia nigra (SN)
Patients often experience rapid loss during weeks 1-12, then a more gradual decline from week 12 onward as the dose levels and the body's metabolic adaptation occurs
Mounjaro, FDA-approved for diabetes), and liraglutide (Saxenda)
How well it retracts on its own depends on how much weight was lost, how fast, your age, your genetics, and the existing quality of your collagen and elastin